NCT00750282 - Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers | Biotech Hunter

Enrollment

422

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Alzheimer DiseaseAmyloid Beta-Protein

Interventions

DRUG

Florbetaben (BAY94-9172)

Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions

Trial Locations (23)

2145

Westmead

3084

Heidelberg

5000

Adelaide

8091

Zurich

10016

New York

10032

New York

10461

The Bronx

13125

Berlin

45122

Essen

48149

Münster

52425

Jülich

81377

München

81675

München

85351

Sun City

91054

Erlangen

94305

Stanford

06510

New Haven

02906

Providence

01307

Dresden

04103

Leipzig

650-0017

Kobe

650-0047

Kobe

113-8603

Bunkyo-ku